- Title
- Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00
- Creator
- Colleoni, Marco; Gray, Kathryb P.; Tondini, Carlo; Kralidis, Elena; Eniu, Alexandru; Cagossi, Katia; Rauch, Daniel; Chirgwin, Jacquie; Gelber, Richard D.; Regan, Meredith M.; Coates, Alan S.; Price, Karen N.; Gelber, Shari; Láng, István; Thürlimann, Beat; Gianni, Lorenzo; Abdi, Ehtesham A.; Gomez, Henry L.; Linderholm, Barbro K.; Puglisi, Fabio
- Relation
- Journal of Clinical Oncology Vol. 34, Issue 28, p. 3400-3408
- Publisher Link
- http://dx.doi.org/10.1200/JCO.2015.65.6595
- Publisher
- American Society of Clinical Oncology
- Resource Type
- journal article
- Date
- 2016
- Description
- Purpose: To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse effects in advanced breast cancer, in early breast cancer. Patients and Methods: International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor- and progesterone receptor-negative (< 10% positive cells by immunohistochemistry) early breast cancer any nodal and human epidermal growth factor receptor 2 status, were randomly assigned anytime between primary surgery and 56 days after the first day of last course of adjuvant chemotherapy to CM maintenance (cyclophosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of every week for 1 year) or to no CM. The primary end point was disease-free survival (DFS), which included invasive recurrences, second (breast and nonbreast) malignancies, and deaths. Results: After a median of 6.9 years of follow-up, DFS was not significantly better for patients assigned to CM maintenance compared with patients assigned to no CM, both overall (hazard ratio [HR], 0.84; 95% CI, 0.66 to 1.06; P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion: CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population.
- Subject
- breast cancer; clinical trial; hormone; risk
- Identifier
- http://hdl.handle.net/1959.13/1342702
- Identifier
- uon:29018
- Identifier
- ISSN:0732-183X
- Language
- eng
- Reviewed
- Hits: 36153
- Visitors: 19788
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|